Identification of glutathione conjugates of troglitazone in human hepatocytes

Chemico-Biological Interactions

Volumn 142, Issue 1-2, 2002, Pages 83-97

  Prabhu, Saileta ^a   Fackett, Andrew ^a   Lloyd, Scott ^a   McClellan, Holly A ^a   Terrell, Chris M ^a   Silber, Paul M ^a   Li, Albert P ^a  

^a In Vitro Technologies Inc   (United States)

Author keywords

Cryopreserved; Glutathione; Hepatocytes; Mass spectrometry; Metabolism; Troglitazone

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; FURAFYLLINE; GLUCURONIDE; GLUTATHIONE; GLUTATHIONE DERIVATIVE; KETOCONAZOLE; OMEPRAZOLE; SULFAPHENAZOLE; SULFATE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

ADULT; AGED; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYOPRESERVATION; DIASTEREOISOMER; DONOR; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; FEMALE; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; LIVER CELL; MALE;

AGED; AGED, 80 AND OVER; CHROMANS; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; GLUCURONIDES; GLUTATHIONE; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; ISOENZYMES; MALE; MASS SPECTROMETRY; MIDDLE AGED; SULFATES; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0037058246     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(02)00056-X     Document Type: Article

References (32)

1. Sparano N., Seaton T.L. Troglitazone in type II diabetes mellitus. Pharmacotherapy. 18:1998;539-548.
2. Spencer C.M., Markham A. Troglitazone. Drugs. 54:1997;89-101. (Discussion 102).
3. Antonucci T., Whitcomb R., McLain R., Lockwood D., Norris R.M. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care. 20:1997;188-193.
4. Davies G.F., Khandelwal R.L., Wu L., Juurlink B.H., Roesler W.J. Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-gamma (PPARgamma)-independent, antioxidant-related mechanism. Biochem. Pharmacol. 62:2001;1071-1079.
5. Davies G.F., McFie P.J., Khandelwal R.L., Roesler W.J. Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes. J. Pharmacol. Exp. Ther. 300:2002;72-77.
6. Camp H.S., Li O., Wise S.C., Hong Y.H., Frankowski C.L., Shen X., et al. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes. 49:2000;539-547.
7. Filz H.P. Insulin sensitizer. A new therapy option for type 2 diabetic patients. MMW Fortschr. Med. 142:2000;31-33.
8. Loi C.M., Young M., Randinitis E., Vassos A., Koup J.R. Clinical pharmacokinetics of troglitazone. Clin. Pharmacokinet. 37:1999;91-104.
9. Loi C.M., Alvey C.W., Randinitis E.J., Abel R., Young M.A., Koup J.R. Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites. J. Clin. Pharmacol. 37:1997;1038-1047.
10. Loi C.M., Randinitis E.J., Vassos A.B., Kazierad D.J., Koup J.R., Sedman A.J. Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study. J. Clin. Pharmacol. 37:1997;1114-1120.
11. Loi C.M., Knowlton P.W., Stern R., Randinitis E.J., Vassos A.B., Koup J.R., et al. Effect of troglitazone on steady-state pharmacokinetics of digoxin. J. Clin. Pharmacol. 38:1998;178-183.
12. Loi C.M., Alvey C.W., Vassos A.B., Randinitis E.J., Sedman A.J., Koup J.R. Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites. J. Clin. Pharmacol. 39:1999;920-926.
13. He K., Woolf T.F., Kindt E.K., Fielder A.E., Talaat R.E. Troglitazone quinone formation catalyzed by human and rat CYP3A: an atypical CYP oxidation reaction. Biochem. Pharmacol. 62:2001;191-198.
14. Yamazaki H., Shibata A., Suzuki M., Nakajima M., Shimada N., Guengerich F.P., et al. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab. Dispos. 27:1999;1260-1266.
15. Ramachandran V., Kostrubsky V.E., Komoroski B.J., Zhang S., Dorko K., Esplen J.E., et al. Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab. Dispos. 27:1999;1194-1199.
16. Sahi J., Hamilton G., Sinz M., Barros S., Huang S.M., Lesko L.J., et al. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica. 30:2000;273-284.
17. Gale E.A. Lessons from the glitazones: a story of drug development. Lancet. 357:2001;1870-1875.
18. Yamamoto Y., Nakajima M., Yamazaki H., Yokoi T. Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. Life Sci. 70:2001;471-482.
19. Yamamoto Y., Yamazaki H., Ikeda T., Watanabe T., Iwabuchi H., Nakajima M., et al. Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. Drug Metab. Dispos. 30:2002;155-160.
20. Yamazaki H., Suzuki M., Tane K., Shimada N., Nakajima M., Yokoi T. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica. 30:2000;61-70.
21. Kostrubsky V.E., Sinclair J.F., Ramachandran V., Venkataramanan R., Wen Y.H., Kindt E., et al. The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures. Drug Metab. Dispos. 28:2000;1192-1197.
22. Toyoda Y., Tsuchida A., Iwami E., Miwa I. Toxic effect of troglitazone on cultured rat hepatocytes. Life Sci. 68:2001;1867-1876.
23. Funk C., Pantze M., Jehle L., Ponelle C., Scheuermann G., Lazendic M., et al. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology. 167:2001;83-98.
24. Funk C., Ponelle C., Scheuermann G., Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 59:2001;627-635.
25. Li A.P., Reith M.K., Rasmussen A., Gorski J.C., Hall S.D., Xu L., et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem. Biol. Interact. 107:1997;17-30.
26. Easterbrook J., Lu C., Sakai Y., Li A.P. Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab. Dispos. 29:2001;141-144.
27. Li A.P., Lu C., Brent J.A., Pham C., Fackett A., Ruegg C.E., et al. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem. Biol. Interact. 121:1999;17-35.
28. Kassahun K., Pearson P.G., Tang W., McIntosh I., Leung K., Elmore C., et al. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 14:2001;62-70.
29. Tettey J.N., Maggs J.L., Rapeport W.G., Pirmohamed M., Park B.K. Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem. Res. Toxicol. 14:2001;965-974.
30. Hanefeld M. Pharmacokinetics and clinical efficacy of pioglitazone. Int. J. Clin. Pract. Suppl. 2001;19-25.
31. Isley W.L., Oki J.C. Rosiglitazone and liver failure. Ann. Intern. Med. 133:2000;393-394.
32. Blickle J.F. Thiazolidinediones: clinical data and perspectives. Diabetes Metab. 27:2001;279-285.